(AOF) – Ikonisys, medtech specializing in the early and precise detection of cancer thanks to a fully automated solution for medical diagnostic laboratories, announces that it has finalized the acquisition of Hospitex International Srl, through the issue of 2 million new Ikonisys shares in favor of ETH Scientific Srl, former owner of Hospitex.
As communicated in November 2023, Ikonisys had signed an agreement for the acquisition of 100% of Hospitex International Srl for 4.5 million euros, paid by the issue of 2 million new Ikonisys shares at a price of 2.25 € per share. As presented in the half-year results, the acquisition of Hospitex was finalized in April 2024. This issue of shares for the benefit of the former owner of Hospitex constitutes the last formal step.
Following the strategic acquisition of Hospitex, Ikonisys introduced a new corporate identity and a renewed commercial vision under the brand “ALIKO SCIENTIFIC” and its slogan “Next Generation Cancer Diagnostics”, marking the transformation of the Group into a dedicated global hub for new generation oncological diagnosis.
AOF – LEARN MORE
